Breaking News
1 hour ago
Simantini Singh Deo
Stipple Bio names Roland Gendron as CBO to lead business development and partnerships as STP-100 advances toward clinical studies on the back of a $100M Series A financing.
Simantini Singh Deo
Akari Therapeutics appoints Dr. Patricia LoRusso to its Scientific Advisory Board as AKTX-101, its TROP2-targeting ADC with RNA splicing payload, targets a Phase I first-in-human trial in mid-2027.
Simantini Singh Deo
Kymera names Dr. Elizabeth Laws SVP to lead KT-621 oral STAT6 degrader program as Phase IIb trials in atopic dermatitis and asthma near registrational stage.
Simantini Singh Deo
ImageneBio appoints Matt Robbins as General Counsel effective July 7, 2026, to lead legal and IP strategy as IMG-007 advances in Phase II trials for atopic dermatitis and alopecia areata.
Simantini Singh Deo